How to best standardise imaging result from multi centre clinical trials
SMi present their 8th annual conference on.........
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London
/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.
Leading speakers include:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK
View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.
http://www.smi-online.co.uk/cancer-imaging38.asp
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London
/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.
Leading speakers include:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK
View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.
http://www.smi-online.co.uk/cancer-imaging38.asp
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.